Details of the Drug

General Information of Drug (ID: DMJKWMA)

Drug Name
Tanezumab
Indication
Disease Entry ICD 11 Status REF
Cancer related pain MG30 Phase 3 [1]
Chronic low back pain MG30.02 Phase 3 [2]
Neuropathic pain 8E43.0 Phase 3 [2]
Osteoarthritis FA00-FA05 Phase 3 [2]
Pain MG30-MG3Z Phase 3 [2]
ATC Code
N02BG12: Tanezumab
N02BG: Other analgesics and antipyretics
N02B: OTHER ANALGESICS AND ANTIPYRETICS
N02: ANALGESICS
N: NERVOUS SYSTEM
Drug Type
Monoclonal antibody
Cross-matching ID
UNII
EQL0E9GCX1
DrugBank ID
DB12335
TTD ID
D00BVS
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Nerve growth factor (NGF) TTDN3LF NGF_HUMAN Inhibitor [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Cancer related pain
ICD Disease Classification MG30
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Nerve growth factor (NGF) DTT NGF 5.57E-02 -0.06 -0.31
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8415).
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)